Related Experiment Videos
Emerging therapies for rectal cancer
1Royal Marsden Hospital, Sutton, Surrey, UK.
Summary
New preoperative strategies for rectal cancer, including novel chemotherapy combinations and targeted agents, aim to improve patient survival beyond current radiotherapy options. Research is exploring these to personalize treatment for better outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Short-course radiotherapy and chemoradiotherapy (CRT) are standard preoperative treatments for operable rectal cancer to reduce local recurrence.
- Current strategies require improvement, particularly in enhancing patient survival rates.
Purpose of the Study:
- To explore novel preoperative treatment strategies for operable rectal cancer.
- To investigate advancements in chemotherapy and targeted agents for improved patient outcomes.
Main Methods:
- Review of current clinical research into alternative radio-sensitizers during CRT.
- Exploration of neoadjuvant chemotherapy prior to preoperative CRT and surgery.
Main Results:
- Advances in metastatic disease treatment inform new preoperative approaches.
- Combination chemotherapy (oxaliplatin, irinotecan) and targeted agents (bevacizumab, cetuximab) show promise.
Conclusions:
- Experimental preoperative treatments are being developed to enhance rectal cancer management.
- Future strategies will focus on tailoring treatments to individual patient needs for improved survival.